Axidin is a histamine H2-receptor antagonist. Axidin completely inhibits the action of histamine on H2-receptors of parietal cell. It inhibits basal, overnight and pentagastrin stimulated gastric acid secretion. The H2-receptor antagonist activity of Axidin is slowly reversible, since the drug dissociates slowly from H2-receptor.
Axidin is used for-
- Short term treatment of active duodenal ulcer and benign gastric ulcer
- Maintenance therapy for prevention of relapses of duodenal ulceration
- Gastro-oesophageal reflux disease
- Zollinger Ellison Syndrome
Axidin is also used to associated treatment for these conditions: Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions, Symptomatic non-erosive gastroesphageal reflux disease
|Other Names||Famotidina, Famotidine, Famotidinum|
The protein binding of famotidine is about 15 to 22%.
|Therapeutic Class||H2 receptor antagonist|
|Manufacturer||Unimed Unihealth MFG, Ltd|
|Last Updated:||June 23, 2021 at 11:20 am|
Table Of contents
Duodenal ulcer: 40 mg at night for 4 to 8 weeks
Benign gastric ulcer: 40 mg at night for 4 to 8 weeks; Maintenance therapy: 20 mg at night for preventing the recurrences of duodenal ulceration
Gastro-oesophageal reflux disease: 20 mg twice daily for 6 to 12 weeks
Zollinger Ellison syndrome: The recommended starting dose is 20 mg every six hours. Dosage should then be adjusted to individual response. Doses up to 160 mg every six hours have been administered to some patients without the development of significant adverse effects.
Dosage can be administered irrespective of meals. Antacids may be given concomitantly if needed.
Axidin is generally well tolerated and side effects are uncommon. Dizziness, headache, constipation and diarrhoea have been reported rarely. Other side effects reported less frequently include dry mouth, nausea and/or vomiting, rash, abdominal discomfort, anorexia and fatigue.
Dosage reduction should be considered or interval between doses should be prolonged if creatinine clearance falls to or below 30 ml/min.
Axidin does not interact with the cytochrome P450 linked drug metabolising enzyme system. So, no interactions have been found in man with Warfarin, Theophylline, Phenytoin, Diazepam, Propranolol, Aminopyrine or antipyrine.
- Avoid excessive or chronic alcohol consumption. Alcohol increases the risk of gastric irritation.
- Limit caffeine intake. Caffeine and other acidic beverages increases the risk of gastric irritation.
- Take with or without food. Food slightly increases bioavailability, but not to a clinically significant extent.
Volume of Distribution
The steady-state volume of distribution ranges from 1.0 to 1.3 L/kg. Axidin is found in breast milk; however, it is found in breast milk at the lowest concentrations compared to other H2 receptor antagonists.
The elimination half-life is about 2 to 4 hours. The half-life is expected to increase nonlinearly in patients with decreased renal function.
Renal clearance is 250-450 mL/min, indicating some tubular excretion. Because the renal clearance rate exceeds the glomerular filtration rate, famotidine is thought to be mainly eliminated via both glomerular filtration and renal tubular secretion.
Pregnancy & Breastfeeding use
Pregnancy: There are no adequate, well controlled studies on Axidin in pregnancy, but it is known to cross the placenta and should be prescribed only if clearly needed.
Lactation: It is not known whether Axidin is secreted into human milk, nursing mothers should either stop nursing or stop taking the drug.
There are no known contraindication to Axidin. If any evidence of hypersensitivity appear, the therapy should be discontinued and consultation with physician is required.
Tablet: Store between 15-30° C. Concentrate for injection: Store between 2-8° C.